The Rationale for Glutamatergic Therapy in Alzheimer's Disease
Publisher
Springer New York
Reference53 articles.
1. Bales, K. R., Tzavara, E. T., Wu, S., Wade, M. R., Bymaster, F. P., Paul, S. M., et al. (2006). Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A{beta} antibody. Journal of Clinical Investigation, 116, 825–832. 2. Baudry, M., & Lynch, G. (2001). Remembrance of arguments past: How well is the glutamate receptor hypothesis of LTP holding up after 20 years? Neurobiology of Learning and Memory, 76, 284–297. 3. Beckstrom, H., Julsrud, L., Haugeto, O., Dewar, D., Graham, D. I., Lehre, K. P., et al. (1999). Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. Journal of Neuroscience Research, 55, 218–229. 4. Bell, K. F., Ducatenzeiler, A., Ribeiro-da-Silva, A., Duff, K., Bennett, D. A., & Claudio, C. A. (2006). The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiology of Aging, 27, 1644–1657. 5. Bellocchio, E. E., Reimer, R. J., Fremeau, R. T., Jr., & Edwards, R. H. (2000). Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science, 289, 957–960.
|
|